Graft Function Variability and Slope and Kidney Transplantation Outcomes

Beini Lyu¹, Didier A. Mandelbrot², Arjang Djamali²,³ and Brad C. Astor¹,²

¹Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; ²Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; and ³Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

Introduction: It is critical to identify kidney transplant recipients (KTRs) at higher risk for adverse outcomes, to focus on monitoring and interventions to improve outcomes. We examined the associations between graft function variability and long-term outcomes in KTRs in an observational study.

Methods: We identified 2919 KTRs in the Wisconsin Allograft Recipient Database (WisARD) who had a functioning allograft 2 years posttransplantation and at least 3 outpatient measurements of estimated glomerular filtration rate (eGFR) from 1 to 2 years posttransplantation. Graft function slope was calculated from a linear regression of eGFR, and variability was defined as the coefficient of variation around this regression line. Associations of eGFR variability and slope with death, graft failure, cardiovascular events, and acute rejection were estimated.

Results: Compared to the lowest quartile, the highest quartile of eGFR variability was associated with a higher risk of death (adjusted hazard ratio [HR] = 1.85; 95% CI = 1.23–2.76), but not with a higher risk of graft failure (subhazard ratio = 1.16; 95% CI = 0.85–1.58), independent of eGFR and slope of eGFR. Greater eGFR variability was associated with higher risk of cardiovascular- and infection-related death and cardiovascular events but not malignancy-related death or allograft rejection. Including variability of eGFR significantly improved prediction of mortality but not prediction of graft failure.

Conclusion: Variability of eGFR is independently associated with risk of death, especially cardiovascular disease–related death and cardiovascular events, but not graft failure. Variability of eGFR may help identify KTRs at higher risk for death and cardiovascular events.

Kidney Int Rep (2021) 6, 1642–1652; https://doi.org/10.1016/j.ekir.2021.03.880

KEYWORDS: allograft survival; cardiovascular events; graft function variability; mortality; rejection; transplantation

© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
We aimed to examine the hypothesis that graft function variability, independent of concurrent graft function, slope of graft function, and other traditional risk factors, is associated with long-term outcomes in KTRs and whether these metrics provide additional prognostic information. In addition, we evaluated the associations between graft function variability and cause-specific death and graft loss to further elucidate the potential clinical significance of this indicator.

**MATERIALS AND METHODS**

**Study Design**
The Wisconsin Allograft Recipient Database (WisARD) was initiated to prospectively collect information on all solid organ transplantations performed at the University of Wisconsin. The current study includes all adult patients in WisARD who underwent a primary kidney transplantation between January 2000 and December 2014. Patients who were alive with a functioning graft at 2 years posttransplantation, had at least 3 outpatient serum creatinine measurements between 1 and 2 years posttransplantation, and at least 90 days between the first and last creatinine measurement during this window were included (see Figure S1 for patient selection). This time period was chosen to avoid transient changes in the first year following transplantation and to increase the likelihood that a linear slope would be able to capture eGFR change more accurately. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Measurements of eGFR greater than 150 ml/min per 1.73 m² were excluded. The study was approved by the University of Wisconsin Health Sciences Institutional Review Board.

**Primary Exposures**
Concurrent eGFR level was defined as the last available eGFR level closest to 2 years posttransplantation. For each patient, we fit an ordinary least square (OLS) regression model to all outpatient eGFR measures between 1 and 2 years posttransplantation, and calculated eGFR slope and variability. A linear slope was extracted from these models. Variability was defined as the coefficient of variation (CV) of the regression line in the primary analyses. In the primary analyses, patients were grouped into CV quartiles. The CV was centered at the mean and scaled by its standard deviation when assessed as a continuous variable.

**Outcomes**
Primary outcomes of interest included total graft loss (i.e., death or graft failure), death, death-censored graft failure (DCGF), and death or graft failure as competing risk events. Secondary outcomes included cause-specific death (cardiovascular-, infection-, and malignancy-related death), cause-specific graft loss (due to acute rejection and chronic rejection), de novo ischemic heart disease (IHD) events [see Supplementary Methods for detailed diagnosis], heart failure (HF), and de novo acute rejection. Cause of death and graft loss was defined accordingly to the Transplant Recipient Registration Form of United network for organ sharing (UNOS). All KTRs were followed from 2 years post-transplantation until death, graft failure, loss to follow-up, 10 years of follow-up, or 31 December 2016.

**Statistical Analysis**
Patient characteristics including demographic, transplantation-related, donor-related, laboratory data, variability of immunosuppression level at baseline period, infectious events, and malignancy were collected (see Supplementary Methods for data collection details). Data were presented as mean (SD), median (interquartile interval [IQR]), or frequency (percentage), as appropriate. Differences in continuous variable were tested using 1-way analysis of variance. Differences in categorical variables were tested using the Pearson χ² test.

**Independent Association Between eGFR Variability and Outcomes of Interest**
Associations between eGFR variability and outcomes were assessed by Cox proportional hazard models. The lowest quartile of CV was used as the reference group. Proportional hazard assumption was tested by checking the Schoenfeld partial residuals. Covariates were included in multivariable analyses if the P value for their association with CV quartiles was less than 0.1. Restricted cubic spline models were applied to explore nonlinear associations between eGFR variability as a continuous covariate and outcomes of interest.

Graft failure and death are competing events that might blur the association between eGFR variability and each of the outcomes. We carried out a competing risk analysis using the method of Fine and Gray and assessed the subhazard of the risk of death and subhazard of graft failure.

**Prediction Performance**
We assessed additional prognostic information provided by eGFR, eGFR linear slope, and CV of eGFR for outcomes prediction. We used Cox regression to assess the univariate associations between outcomes of interest and patient characteristics. Patient characteristics that were significantly associated with the outcomes of interest were then included in multivariable analyses. We constructed a base model and a saturated model for prediction comparison. The base model included patient age, sex, race, cause of ESKD, and live donor transplantation. The saturated model further included...
other factors included in the aforementioned multivariable model. Discrimination was assessed by the Harrell concordance index. Calibration was assessed by a visual examination of the calibration plots.

We used continuous net reclassification improvement (NRI) for censored survival data for model performance comparison. The continuous NRI can be interpreted as the sum of the net proportion of events assigned a higher risk and net proportion of non-events assigned to a lower risk. We assessed internal validity by using a bootstrap procedure to generate 1000 datasets from resampling the original dataset and calculated the optimism-corrected 95% confidence interval.

Approximately 20% of participants were missing smoking information and 3.5% were missing serum albumin information. We used multiple imputation to generate 20 datasets by means of a conditional specification approach.

Several sensitivity analyses were conducted to examine the robustness of our results. First, we calculated eGFR slope and variability using log-transformed eGFR measurements. Second, we repeated the analyses within strata of acute rejection, diabetes, peripheral arterial disease (PAD), eGFR at 2 years posttransplantation (<60 vs. ≥60 ml/min per 1.73 m²), and cardiovascular disease (CVD). Third, as eGFR variability might be an indicator of exposure to extrinsic events that compromise graft function and may lead to hospitalization, we limited our analyses to KTRs without hospitalization during the baseline period. Fourth, we further adjusted for body mass index (BMI) at transplantation, induction immunosuppression, delayed graft function, smoking, and race of donor, even though they did not meet the inclusion criterion of $P < 0.1$. Fifth, we limited the analyses to transplantations between 2010 and 2014 to explore potential era effect. Sixth, we excluded outcomes that occurred within 2.5 years posttransplantation to exclude reverse causality (i.e., patients at higher risk for outcomes may result in greater variability). Seven, we repeated the above analyses using mean absolute residuals and root mean square error from eGFR regression models as alternative indicators of variability. Eighth, we repeated the primary analyses using CV of creatinine as the main exposure. All analyses were performed using R (www.R-project.org/).

RESULTS

Characteristics of Study Participants
Among 3771 KTRs who underwent kidney transplantation between 2000 and 2014, a total of 2919 (77.4%) KTRs were included in the study. These recipients had a total of 40,498 serum creatinine measurements during the baseline period. On average, each patient had 14 eGFR measurements (median = 12, IQI = 9–15). Compared to enrolled participants, patients who were excluded from analysis were generally in worse condition: they were more likely to have longer pretransplantation dialysis, greater human leukocyte antigen (HLA) mismatch, acute rejection, delayed graft function, CVD, and diabetes mellitus (DM) (Table S1).

Patients with greater variability were more likely to be female, to have ESKD due to DM, and to have longer pretransplantation dialysis duration (Table 1). Patients with greater variability also were more likely to be diagnosed with CVD, DM, and PAD. In addition, they were more likely to have greater immunosuppression variability, lower serum albumin level at 2 years posttransplantation, higher incidence of hospitalization, and a kidney from a male donor. Patients with higher variability were more likely to have negative eGFR slope, to have a higher eGFR at 2 years, and to have more eGFR measurements between 1 and 2 years posttransplantation. No associations between infectious events or malignancy and eGFR variability were observed.

Total Graft Loss
With a total of 15,504 person-years of follow-up and a median follow-up of 5.1 (IQI = 2.5–8.4) years, approximately 9.9% of KTRs were lost to follow-up, predominately because of transferring to other providers. There were 873 (29.9%) total graft losses. Patients in the highest quartile of eGFR variability had significantly higher risk of total graft loss [hazard ratio (HR) = 1.62 in adjusted analysis] (Table 2, Figure 1a). No significant association was observed for patients in quartile 2 or 3 compared to quartile 1. Higher eGFR level and more positive eGFR slope also were significantly associated with lower risk of total graft loss.

All-Cause Death
There were 506 deaths (17.3%) among study participants. Patients with the highest quartile of variability had a higher risk of death compared to the lowest quartile group (HR = 1.85, 95% CI = 1.23–2.76 in adjusted analysis) (Table 2, Figure 1b). No significant association was observed for patients in quartile 2 or 3 compared to quartile 1. Higher eGFR level was associated with significantly lower risk of mortality. However, eGFR slope was not associated with risk of mortality (Figure S2).
| Characteristic | eGFR coefficient of variation quartile | P value |
|---------------|--------------------------------------|---------|
|               | <7.2% (n = 729) | 7.2%—9.4% (n = 730) | 9.4%—12.1% (n = 729) | ≥12.1% (n = 731) |
| **Recipient characteristics** | | | | |
| Patient age at transplantation, yr | 49.7 (13.4) | 49.5 (14.3) | 50.1 (13.8) | 50.3 (14.5) | 0.69 |
| Sex, male (%) | 500 (68.6) | 470 (64.4) | 400 (54.9) | 323 (44.2) | <0.001 |
| Race (%) | 53 (7.3) | 55 (7.5) | 47 (6.4) | 53 (7.3) | 0.83 |
| Black | 52 (7.1) | 56 (7.7) | 66 (9.1) | 63 (8.6) | |
| Other | 624 (85.6) | 619 (84.8) | 616 (84.5) | 615 (84.1) | |
| White | 27.5 (5.4) | 27.6 (5.3) | 27.2 (5.2) | 27.2 (5.6) | 0.43 |
| **Cause of ESKD** | | | | <0.001 |
| DN | 137 (18.8) | 149 (20.4) | 175 (24.0) | 257 (35.2) | |
| GN | 190 (26.1) | 193 (26.4) | 197 (27.0) | 155 (21.2) | |
| HTN | 72 (9.9) | 84 (11.5) | 63 (8.6) | 57 (7.8) | |
| Others | 212 (29.1) | 199 (27.3) | 186 (25.5) | 193 (26.4) | |
| PKD | 118 (16.2) | 105 (14.4) | 108 (14.8) | 69 (9.4) | |
| Dialysis before transplantation, n (%) | 488 (66.9) | 521 (71.4) | 506 (69.4) | 573 (78.4) | <0.001 |
| Dialysis duration, mo, median (IQI) | 10 (0, 28) | 10 (0, 28) | 11 (0,29) | 14 (2, 32) | <0.001 |
| Year of transplantation | 2007 (2004, 2011) | 2007 (2003,2011) | 2007 (2003, 2010) | 2006 (2003,2010) | 0.011 |
| Prior transplantation | 128 (17.6) | 119 (16.3) | 143 (19.6) | 171 (23.4) | 0.004 |
| HLA_miscat (%) | 0.28 |
| 1 or 2 | 206 (28.3) | 176 (24.1) | 199 (27.3) | 196 (26.8) | |
| 3 or 4 | 287 (39.4) | 303 (41.5) | 312 (42.8) | 284 (38.9) | |
| 5 or 6 | 236 (32.4) | 251 (34.4) | 218 (29.9) | 251 (34.3) | |
| PRA | 4.7 (14.7) | 5.3 (15.3) | 6.5 (17.6) | 6.2 (17.4) | 0.08 |
| **Induction IS (%)** | 0.71 |
| Campath | 134 (18.4) | 149 (20.4) | 145 (19.9) | 147 (20.1) | |
| Others | 44 (6.0) | 38 (5.2) | 33 (4.5) | 33 (4.5) | |
| Simulect | 431 (59.1) | 423 (57.9) | 424 (58.2) | 409 (56.0) | |
| Thymo | 120 (16.5) | 120 (16.4) | 127 (17.4) | 142 (19.4) | |
| **Maintenance IS (%)** | 0.035 |
| CSA | 177 (24.3) | 202 (27.7) | 197 (27.0) | 217 (29.7) | |
| Others | 72 (9.9) | 57 (7.8) | 42 (5.8) | 51 (7.0) | |
| Tacrolimus | 480 (65.8) | 471 (64.5) | 490 (67.2) | 463 (63.3) | |
| Acute rejection | 127 (17.4) | 132 (18.1) | 139 (19.1) | 159 (21.8) | 0.07 |
| Delayed graft function | 93 (12.8) | 103 (14.1) | 99 (13.8) | 109 (14.9) | 0.68 |
| Smoking | 0.23 |
| Current | 50 (6.9) | 42 (5.8) | 46 (6.3) | 37 (5.1) | |
| Never | 374 (51.3) | 395 (54.1) | 372 (51.0) | 375 (51.3) | |
| Post | 229 (31.4) | 218 (29.9) | 231 (31.7) | 213 (29.1) | |
| Missing | 76 (10.4) | 75 (10.2) | 80 (11.3) | 106 (14.5) | |
| Cardiovascular disease | 198 (27.2) | 203 (27.8) | 230 (31.6) | 247 (33.8) | 0.016 |
| Diabetes | 162 (22.2) | 170 (23.3) | 196 (28.9) | 282 (38.6) | <0.001 |
| Peripheral arterial disease | 39 (5.3) | 46 (6.3) | 50 (6.9) | 77 (10.5) | 0.001 |
| CMV infection | 81 (11.1) | 77 (10.5) | 94 (12.9) | 97 (13.3) | 0.30 |
| BK infection | 96 (13.2) | 88 (12.1) | 88 (12.1) | 76 (10.4) | 0.44 |
| Malignancy | 78 (10.7) | 84 (11.5) | 77 (10.6) | 81 (11.1) | 0.94 |
| Incidence of hospitalization between 1 and 2 years, per person-year | 0.29 | 0.31 | 0.38 | 0.85 | <0.001 |
| Serum albumin, g/dl | 3.97 (0.44) | 3.97 (0.41) | 3.95 (0.45) | 3.85 (0.49) | <0.001 |
| Percentage in lowest quartile of maintenance IS | 151 (20.7) | 145 (19.9) | 175 (24.0) | 182 (24.9) | 0.09 |
| CV of IS, median (IQI) | 23.7 (16.5, 37.1) | 25.7 (17.7, 38.8) | 25.9 (18.5, 37.8) | 32.8 (22.9, 48.2) | <0.001 |
| **Donor characteristics** | | | | |
| Live donor | 334 (45.8) | 337 (46.2) | 303 (41.6) | 297 (40.6) | 0.064 |
| Age of donor, yr | 43.6 (14.9) | 42.4 (13.7) | 41.4 (14.4) | 41.3 (14.7) | 0.008 |
| Donor sex, male | 369 (50.6) | 360 (49.3) | 418 (57.3) | 404 (55.3) | 0.005 |
| Donor race | 0.78 |
| Black | 13 (1.8) | 16 (2.2) | 17 (2.3) | 19 (2.6) | |
| Other | 33 (4.5) | 27 (3.7) | 35 (4.8) | 38 (5.2) | |
| White | 683 (93.7) | 687 (94.1) | 677 (92.9) | 674 (92.2) | |

(Continued on following page)
Death-Censored Graft Failure
There were 367 DCGFs among study participants. No significant association was observed between eGFR variability and the risk of DCGF (highest quartile: HR = 1.10, 95% CI = 0.83–1.45 in unadjusted analysis; HR = 1.17, 95% CI = 0.85–1.61 in adjusted analysis) (Table 2). In contrast, higher eGFR level and more positive eGFR slope were both associated with significantly lower risk of DCGF (adjusted HR = 0.76, 95% CI = 0.70–0.83 per 10 ml/min per 1.73 m² for eGFR level; HR = 0.92, 95% CI = 0.86–0.99 per ml/min per 1.73 m² per year for eGFR slope).

Death or Graft Failure in Competing Risk Analysis
In competing risk analysis, patients in the highest quartile of variability exhibited a significantly higher risk of death (subhazard ratio [subHR] = 1.50, 95% CI = 1.10–2.04 in adjusted analysis) (Table 3), but not higher risk of graft failure (subHR = 1.16, 95% CI = 0.85–1.58). Similar results were observed in cumulative incidence estimates of death and graft failure (Figure 2). Conversely, higher eGFR level and more positive eGFR slope were associated with lower risk of graft failure but not risk of death.

The above-mentioned associations remained consistent in models including CV as a continuous variable, with higher risk of total graft loss and death mainly among KTRs with high variability (Figure 2b and 3b). No significant association between CV and risk of DCGF was found (Figure S3).

Secondary Outcomes: Cause-Specific Death, Graft Loss Due to Acute and Chronic Rejection, De Novo Cardiovascular Events, and De Novo Acute Rejection
Considering that KTRs in the lower 3 CV quartiles had similar risk of death and graft loss in the primary results, we grouped the lower 3 quartiles as the reference group.

There were 91 CVD-related deaths, 106 infection-related deaths, and 86 malignancy-related deaths among study participants. Greater variability was associated with higher risk of CVD-related death (adjusted HR = 2.32, 95% CI = 1.50–3.61 of quartile 4 compared with the lower 3 quartiles) (Table 4). Greater variability also was associated with higher risk of infection-refered death (adjusted HR = 1.65, 95% CI = 1.10–2.49 of quartile 4 vs. quartiles 1–3). However, no association between variability and malignancy-related death was found (adjusted HR = 1.35, 95% CI = 0.83–2.19).

There were 37 graft losses due to acute rejection and 204 graft losses due to chronic rejection. No significant association between variability and graft loss due to acute rejection or chronic rejection was found (adjusted HR = 1.12, 95% CI = 0.53–2.36 for graft loss due to acute rejection; adjusted HR = 0.94, 95% CI = 0.68–1.30 for graft loss due to chronic rejection).

Among 1776 patients with no diagnosis of IHD at 2 years posttransplantation, 171 IHD events were diagnosed. Greater variability was associated with higher risk of IHD (adjusted HR = 1.62, 95% CI = 1.15–2.28). Similarly, greater variability was associated with higher risk of heart failure (adjusted HR = 1.76, 95% CI = 1.23–2.53). Among 2362 patients with no diagnosis of acute rejection at 2 years posttransplantation, 282 acute rejection events were diagnosed. No association between variability and acute rejection was observed (adjusted HR = 1.05, 95% CI = 0.73–1.47).

Prediction Improvement of eGFR Level, Slope, and Variability
Bivariable and Multivariable Analyses
We first investigated the prognostic factors that were associated with risk of mortality and risk of DCGF in bivariable analyses (Tables S2 and S3). In multivariable analyses, the following independent predictors of long-term risk of mortality were identified: age at transplantation, sex, prior transplantation, acute rejection, cardiovascular disease, previous hospitalization,

---

Table 1. (Continued)

| Characteristic | eGFR coefficient of variation quartile |
|---------------|---------------------------------------|
|               | <7.2% (n = 729) | 7.2%–9.4% (n = 730) | 9.4%–12.1% (n = 729) | ≥12.1% (n = 731) | P value |
| eGFR measure characteristics | | | | | |
| Last observed eGFR at 2 yr | 60.7 (21.7) | 61.9 (17.9) | 62.9 (17.9) | 63.0 (19.6) | 0.075 |
| Slope of eGFR, ml/min per 1.73 m² per yr | 0.67 (9.62) | 1.08 (11.80) | 0.33 (12.21) | -0.70 (17.24) | 0.058 |
| RMSE | 3.14 (1.39) | 5.09 (1.46) | 6.70 (1.80) | 9.76 (3.30) | <0.001 |
| Mean absolute residuals | 2.26 (1.05) | 3.74 (1.09) | 4.96 (1.42) | 7.21 (2.53) | <0.001 |
| Number of eGFR measurement | 10.1 (4.4) | 13.0 (6.4) | 14.2 (6.8) | 17.6 (13.3) | <0.001 |
| Interval between first and last eGFR measurement, days | 301.9 (58.7) | 319.6 (41.1) | 324.8 (37.8) | 321.3 (39.6) | <0.001 |

BMI, body mass index; BK, ; CMV, cytomegalovirus; CSA, cyclosporine; CV, coefficient of variation; DN, diabetic nephropathy; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; GN, glomerulonephritis; HLA_miscat, ; HTN, hypertension nephropathy; IQI, interquartile interval; IS, immunosuppression; PKD, polycystic kidney disease; PRA, panel reactive antibody; RMSE, root mean square error.
Including eGFR, slope of eGFR, and CV resulted in NRI of 0.263 (0.114–0.343) for 1-year risk prediction (C index 0.786, 95% CI = 0.742–0.822). The CV alone and combined with eGFR and slope provided less information in the saturated model compared to that in the base model, but still significantly improved prediction for 1- and 3-year mortality. The calibration plot showed good agreement between the predicted and observed mortality (Figure S4). Similarly, the CV of eGFR provided additional information on risk of total graft loss, especially in short-term follow-up (Table S4).

**Prediction of DCGF**

The CV of eGFR was not independently predictive of DCGF. Including CV in the base model resulted in NRI of 0.055 (−0.193 to 0.201) for 1-year DCGF risk prediction (Table 6). In contrast, the eGFR level provided substantial prognostic information on risk of DCGF (NRI 0.252 (0.098–0.365) for 1-year risk of DCGF, and NRI 0.213 (0.153–0.307) for 10-year risk of DCGF prediction). Including eGFR slope in models also significantly improved DCGF risk prediction in both the base model and the saturated model. The calibration plot showed good agreement between the predicted and observed risk of graft failure (Figure S5).

**Results of Sensitivity Analyses**

Results were similar in analyses using a log-linear regression model for eGFR. Patients in the highest quartile of log-eGFR variability were at higher risk for death but not graft failure (subHR = 1.7, 95% CI =

---

Table 2. Quartiles of eGFR CV and the risk of total graft loss and death

| Quartiles of eGFR CV (%) | Total Graft Loss, n (%) | Unadjusted | Adjusted * |
|-------------------------|-------------------------|------------|------------|
| CV Q1 (<7.2%) (n = 729) | 197 (27.0)              | 1.0 (Ref)  | 1.0 (Ref)  |
| CV Q2 (7.2%–9.4%) (n = 730) | 197 (27.0)              | 0.95 (0.78–1.16) | 1.00 (0.81–1.23) |
| CV Q3 (9.4%–12.1%) (n = 729) | 183 (25.1)              | 0.87 (0.71–1.06) | 0.91 (0.73–1.13) |
| CV Q4 (≥12.1%) (n = 732) | 296 (40.4)              | 1.50 (1.26–1.80) | 1.33 (1.08–1.62) |

For eGFR per 10 ml/min per 1.73 m² per yr:

| Quartiles of eGFR CV (%) | Total Graft Loss, n (%) | Unadjusted | Adjusted * |
|-------------------------|-------------------------|------------|------------|
| CV Q1 (<7.2%) (n = 729) | 103 (14.1)              | 1.0 (Ref)  | 1.0 (Ref)  |
| CV Q2 (7.2%–9.4%) (n = 730) | 109 (14.9)              | 1.01 (0.77–1.32) | 0.98 (0.74–1.30) |
| CV Q3 (9.4%–12.1%) (n = 729) | 101 (13.9)              | 0.92 (0.70–1.21) | 0.88 (0.66–1.18) |
| CV Q4 (≥12.1%) (n = 732) | 193 (26.4)              | 1.87 (1.47–2.38) | 1.47 (1.13–1.92) |

For slope of eGFR per 5 ml/min per 1.73 m² per yr:

| Quartiles of eGFR CV (%) | Total Graft Loss, n (%) | Unadjusted | Adjusted * |
|-------------------------|-------------------------|------------|------------|
| CV Q1 (<7.2%) (n = 729) | 94 (12.9)               | 1.0 (Ref)  | 1.0 (Ref)  |
| CV Q2 (7.2%–9.4%) (n = 730) | 88 (12.1)               | 0.89 (0.67–1.19) | 1.02 (0.75–1.39) |
| CV Q3 (9.4%–12.1%) (n = 729) | 82 (11.2)               | 0.81 (0.61–1.10) | 0.92 (0.67–1.27) |
| CV Q4 (≥12.1%) (n = 732) | 103 (14.1)              | 1.10 (0.83–1.45) | 1.17 (0.85–1.61) |

For eGFR per 10 ml/min per 1.73 m² per yr:

| Quartiles of eGFR CV (%) | Total Graft Loss, n (%) | Unadjusted | Adjusted * |
|-------------------------|-------------------------|------------|------------|
| CV Q1 (<7.2%) (n = 729) | 79 (11.2)               | 0.83 (0.67–1.19) | 0.95 (0.75–1.39) |
| CV Q2 (7.2%–9.4%) (n = 730) | 77 (10.9)               | 0.80 (0.62–1.06) | 0.99 (0.75–1.30) |
| CV Q3 (9.4%–12.1%) (n = 729) | 74 (10.6)               | 0.77 (0.57–1.03) | 0.76 (0.55–1.06) |
| CV Q4 (≥12.1%) (n = 732) | 81 (11.5)               | 0.74 (0.54–1.03) | 0.71 (0.51–1.01) |

Model adjusted for patient age at transplantation, sex, race, cause of ESKD, CVD, PAD, hospitalization between 1 and 2 years posttransplantation, pretransplantation dialysis, and pretransplantation dialysis duration, prior transplantation, PRA, year of transplantation, maintenance immunosuppressant level and variability, acute rejection, and albumin level, live donor, age and sex of donor, last observed eGFR, annual slope of eGFR, and number of eGFR measurement between 1 and 2 years.

CV, coefficient of variation; CVD, cardiovascular disease; DCGF, death-censored graft failure; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; PAD, peripheral arterial disease; Q, quartile; Ref, reference.

*P < 0.05.

*P < 0.001.

*P < 0.01.
1.3–2.2 for death; subHR = 1.2, 95% CI = 0.9–1.6 for graft failure) (Table S5).

There was limited evidence of any interaction between eGFR variability and acute rejection, diabetes, PAD, eGFR category at 2 years, or history of CVD ($P$ for interaction >0.1 for all). However, slightly stronger associations between CV and risk of death were observed in KTRs who were doing relatively well (i.e., no acute rejection, no diabetes, no PAD, or better graft function) (Table S6). Among 2193 KTRs (75.1%) who had no hospitalization between 1 and 2 years posttransplantation, results remained consistent (Table S7). The results remained similar in analyses limited to transplantations between 2010 and 2014 (Table S8), excluding outcomes that occurred within 2.5 years posttransplantation (Table S9), and using CV of creatinine as the main exposure (Table S10). The associations between mean absolute residuals and RMSE and outcomes of interest were consistent with the main results (Table S11 and Table S12). The results were consistent in analyses further adjusted for BMI at transplantation, induction immunosuppressant, delayed graft function, smoking, and race of donor (data now shown).

**DISCUSSION**

In a large cohort of kidney transplant recipients, variability of eGFR between 1 and 2 years posttransplantation was associated with higher risk of death but not graft failure. The association was independent of both traditional baseline characteristics and other markers of graft function, including eGFR and slope of eGFR. Greater eGFR variability was associated with higher risk of cardiovascular- and infection-related death and cardiovascular events but

![Figure 1. Kaplan–Meier curves of survival probability of (a) total graft loss and (b) death across estimated glomerular filtration rate (eGFR) coefficient of variation quartiles. Here follow-up time started after baseline period (i.e., 2 years posttransplantation). CV, coefficient of variation; Q, quartile.](image-url)
not malignancy-related death or acute rejection. Including eGFR variability in models improved prediction of mortality. Conversely, eGFR level and eGFR slope were significantly associated with and improved prediction of graft failure. Our results suggest that dynamic changes in eGFR during 1 and 2 years post-transplantation may help to identify patients at higher risk for cardiovascular death or cardiovascular events, and may provide important prognostic information for long-term outcomes.

Our results on graft function variability associated with higher risk of death, independent of eGFR, eGFR slope, and other risk factors, are consistent with previous work in the native CKD population.4,6,15 Specifically, greater graft function variability was associated with higher risk of CVD- and infection-related death. In addition, greater variability was associated with greater risk of CVD events. These results suggest that variability may be an indicator of vascular condition or subclinical vascular disease. It is possible that the association between variability and infection-related death also is related to vascular condition, as patients with worse vascular condition are more fragile and at higher risk for death from a given infectious episode. Consistently across studies4,6,7 as well as in our own data, greater eGFR variability was observed in patients with diabetes, CVD, and PAD. These results further supported variability of graft function as a marker of vascular disease.

In contrast, we did not find any associations between graft function variability and risk of graft failure or acute rejection. This is consistent with a previous study in CKD patients in which variability of eGFR was not associated with ESKD progression.13 Extrinsic events, such as hospitalization, acute rejection, and poor adherence to immunosuppressant, may compromise graft function and result in greater graft function variability. However, after accounting for these factors, graft function variability was not associated with higher risk of graft failure or acute rejection. Altogether, our results support that graft function variability is less a marker of graft health per se, but is more likely an indicator of vascular disease. In our work, the associations were limited mainly to those in the highest quartile of graft function variability, as also observed in previous studies.4,6 These findings suggest a threshold effect, such that the associations with CVD events or death may be apparent only when the underlying vascular condition is worse than a certain threshold. As such, assessment of eGFR variability may provide valuable information in KTRs, especially for cardiovascular-related death and cardiovascular events.

We observed strong associations between eGFR level and slope and risk of graft failure. This also is consistent with previous studies in transplant recipients.16-18 Clayton et al. showed that a 30% decline in eGFR between 1 and 3 years post-transplantation is strongly associated with risk of death-censored graft failure.18 However, in contrary to previous work,18,19 we did not find significant associations between eGFR level and slope and mortality in multivariable analyses. There are several possible explanations for the null associations. First, similar to variability of eGFR, decline in eGFR is probably a surrogate marker of patient characteristics.
Table 4. Association between eGFR variability and cause-specific death, graft loss due to acute and chronic rejection, de novo cardiovascular events, and acute rejection

| Death                                      | No. of events, n (%) | Unadjusted HR (95% CI)     | Adjusted HR (95% CI) |
|--------------------------------------------|----------------------|--------------------------|----------------------|
| CVD-related death                          |                      |                          |                      |
| CV_quartile [Q1–Q3], n = 2188               | 51 (2.3)             | 1.0 (Ref)                | 1.0 (Ref)            |
| CV_quartile [Q4], n = 731                  | 40 (5.5)             | 2.43 (1.60–3.67)         | 2.32 (1.50–3.61)     |
| Infection-related death                    |                      |                          |                      |
| CV_quartile [Q1–Q3], n = 2188               | 62 (2.8)             | 1.0 (Ref)                | 1.0 (Ref)            |
| CV_quartile [Q4], n = 731                  | 44 (6.0)             | 2.19 (1.49–3.23)         | 1.65 (1.10–2.49)     |
| Malignancy-related death                   |                      |                          |                      |
| CV_quartile [Q1–Q3], n = 2188               | 60 (2.7)             | 1.0 (Ref)                | 1.0 (Ref)            |
| CV_quartile [Q4], n = 731                  | 26 (3.6)             | 1.35 (0.85–2.13)         | 1.35 (0.83–2.19)     |
| Graft loss                                 |                      |                          |                      |
| Acute rejection-related                    |                      |                          |                      |
| CV_quartile [Q1–Q3], n = 2188               | 26 (1.2)             | 1.0 (Ref)                | 1.0 (Ref)            |
| CV_quartile [Q4], n = 731                  | 11 (1.5)             | 1.28 (0.63–2.60)         | 1.12 (0.53–2.36)     |
| Chronic rejection related                  |                      |                          |                      |
| CV_quartile [Q1–Q3], n = 2188               | 148 (6.8)            | 1.0 (Ref)                | 1.0 (Ref)            |
| CV_quartile [Q4], n = 731                  | 56 (7.7)             | 1.19 (0.87–1.61)         | 0.94 (0.68–1.30)     |
| Ischemic heart disease*                    |                      |                          |                      |
| CV_quartile [Q1–Q3], n = 1378              | 117 (8.5)            | 1.0 (Ref)                | 1.0 (Ref)            |
| CV_quartile [Q4], n = 398                  | 54 (13.6)            | 1.61 (1.16–2.22)         | 1.62 (1.15–2.28)     |
| Heart failure*                             |                      |                          |                      |
| CV_quartile [Q1–Q3], n = 1882              | 88 (4.7)             | 1.0 (Ref)                | 1.0 (Ref)            |
| CV_quartile [Q4], n = 612                  | 52 (8.5)             | 1.87 (1.33–2.63)         | 1.76 (1.23–2.53)     |
| Acute rejection*                           |                      |                          |                      |
| CV_quartile [Q1–Q3], n = 1790              | 200 (9.1)            | 1.0 (Ref)                | 1.0 (Ref)            |
| CV_quartile [Q4], n = 572                  | 82 (11.2)            | 1.05 (0.75–1.47)         | 1.05 (0.73–1.47)     |

CV, coefficient of variation; Q, quartile.  
*Adjusted for age at transplantation, sex, prior transplantation, acute rejection, cardiovascular disease, previous hospitalization, and albumin level.  
*Analyses limited to patients without prior diagnosis of ischemic heart disease, heart failure, or acute rejection, respectively.

and posttransplantation events, including acute rejection, immunosuppressant toxicity, donor-derived lesions, and so forth. Covariates in our multivariable analyses may be the causal factors between eGFR and mortality and thus explained away the association. Second, we assumed a linear slope between 1 and 2 years posttransplantation instead of allowing a potentially nonlinear pattern. This may miss the true association, and part of the residual association was then captured by variability and risk of mortality.

It is relatively easy to implement an algorithm to capture eGFR level and to calculate eGFR slope and variability in clinical practice with widely available electronic health records. Variability of eGFR is likely an indicator of vascular condition and can be applied to identify patients at higher risk for death and

Table 5. Continuous net reclassification index in mortality risk prediction after including CV

| Mortality risk | 1 yr* | 3 yr* | 5 yr* | 10 yr* |
|----------------|-------|-------|-------|--------|
| Base model     |       |       |       |        |
| + CV           | 0.216 (0.041, 0.321)* | 0.161 (0.058, 0.238)* | 0.109 (0.002, 0.173)* | 0.08 (0.021, 0.131)* |
| + last_EGFR    | 0.068 (0.062, 0.180)  | 0.111 (0.07, 0.180)   | 0.088 (0.002, 0.135)  | 0.096 (0.004, 0.174)  |
| + slope_yr     | 0.003 (0.176, 0.127)  | 0.007 (0.135, 0.101)  | 0.014 (0.081, 0.082)  | 0.029 (0.085, 0.087)  |
| + CV, eGFR, and slope | 0.283 (0.114, 0.343)* | 0.227 (0.083, 0.300)* | 0.161 (0.066, 0.221)* | 0.096 (0.019, 0.183)* |
| Saturated model |       |       |       |        |
| + CV           | 0.097 (0.016, 0.166)  | 0.072 (0.001, 0.132)  | 0.037 (0.067, 0.111)  | 0.114 (0.006, 0.228)  |
| + last_EGFR    | 0.009 (0.07, 0.173)   | 0.096 (0.093, 0.173)  | 0.126 (0.065, 0.171)  | 0.054 (0.012, 0.168)  |
| + slope_yr     | -0.019 (0.13, 0.097)  | -0.018 (0.074, 0.066) | 0.008 (0.066, 0.073)  | 0.034 (0.015, 0.092)  |
| + CV, eGFR, and slope | 0.117 (0.001, 0.213)* | 0.077 (0.003, 0.147)* | 0.042 (0.02, 0.156) | 0.164 (0.005, 0.251) |

Base model included age, sex, race, cause of end-stage kidney disease (ESKD), and live donor. Saturated model included patient age at transplantation, sex, race, cause of ESKD, cardiovascular disease, peripheral arterial disease, hospitalization between 1 and 2 years posttransplantation, pretransplantation dialysis, and pretransplantation dialysis duration, prior transplantation, panel reactive antibody, year of transplantation, maintenance immunosuppressant level and variability, acute rejection, and albumin level, live donor, age and sex of donor, last observed eGFR, annual slope of eGFR, and number of eGFR measurements between 1 and 2 years.  
*CV, coefficient of variation; eGFR, estimated glomerular filtration rate.  
*Here follow-up time started after baseline period (i.e., 2 years posttransplantation).  
P < 0.01.  
*P < 0.05.
cardiovascular events. Our results showed that variability of eGFR improved mortality risk prediction, whereas eGFR level and slope improved graft failure prediction. Incorporating these metrics may help to identify patients at higher risk for adverse outcomes. External studies incorporating eGFR variability among kidney transplantation recipients are needed to validate these findings and to assess the potential impact.

Our study has several strengths. First, WisARD provides detailed patient information, allowing us to account for a large number of potential confounders. Second, using competing risk analyses, we were able to disentangle the association between eGFR variability and death versus graft failure. Third, we used model-based metrics for variability, which are able to incorporate eGFR slope over time. Our results are robust, given the good agreement in results using alternative variability indicators as well as a different modeling strategy for the eGFR trajectory. Fourth, checking cause-specific death and graft failure further illustrated potential underlying mechanism associated with eGFR variability.

Our study also has limitations. We excluded patients who did not have a functioning graft at 2 years post-transplantation and who did not have an adequate number of outpatient eGFR measurements between 1 and 2 years. Participants included in the analyses were healthier and may have had lower eGFR variability. More advanced modeling strategies that are able to incorporate complicated patterns of eGFR trajectory early post-transplantation and survival outcomes, such as joint modeling, are needed to explore their etiologic associations. Second, our results may be affected by ascertainment bias, as patients with more eGFR measurements had greater variability and higher risk of adverse outcomes. We adjusted for number of glomerular filtration rate (GFR) measurements in analyses, but potential bias may still remain. Third, our findings are limited by the potential for measurement error in graft function introduced by using serum creatinine and eGFR rather than directly measured GFR. Fourth, we did not have data on some important covariates such as proteinuria and dosage change of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. Fifth, we assumed a linear slope of eGFR in the baseline period. It is possible that eGFR may have a nonlinear change pattern over time. However, we limited the baseline period to 1 and 2 years post-transplantation, and we expect a less complicated eGFR change than earlier posttransplantation. Sixth, we applied only internal validation by bootstrap. External validation studies are needed to further demonstrate applicability of our results.

In summary, in a large transplantation cohort, greater variability in eGFR between 1 and 2 years post-transplantation was strongly associated with an increased risk of death that is independent of traditional prognostic factors, eGFR level, and eGFR slope, but not increased risk of graft failure. Specifically, greater variability of eGFR was associated with higher risk of cardiovascular- and infection-related death and cardiovascular events. Our work demonstrates that using these eGFR metrics may help to identify patients at higher risk for adverse transplantation outcomes.

**DISCLOSURE**

All the authors declared no competing interests.

BL was supported by American Heart Association 2020 Student Scholarships in Cardiovascular Disease.

**AUTHOR CONTRIBUTIONS**

BL and BCA designed the study; BL and BCA analyzed the data; BL, DAM, AD, and BCA interpreted the data; BL

---

**Table 6. Continuous net reclassification index in risk of death censored graft loss risk prediction after including CV**

| Mortality risk | 1 yr<sup>a</sup> | 3 yr<sup>b</sup> | 5 yr<sup>c</sup> | 10 yr<sup>d</sup> |
|---------------|-----------------|----------------|----------------|-----------------|
| Base model    |                 |                |                |                 |
| + CV          | 0.055 (−0.193, 0.201) | 0.005 (−0.210, 0.203) | 0.003 (−0.190, 0.232) | 0.002 (−0.225, 0.240) |
| + last_EGFR   | 0.252 (0.098, 0.365)<sup>e</sup> | 0.238 (0.171, 0.327)<sup>e</sup> | 0.251 (0.167, 0.343)<sup>e</sup> | 0.213 (0.153, 0.307)<sup>e</sup> |
| + slope_yr    | 0.091 (−0.062, 0.210) | 0.124 (0.039, 0.225)<sup>e</sup> | 0.157 (0.077, 0.228)<sup>e</sup> | 0.158 (0.052, 0.210)<sup>e</sup> |
| + CV, eGFR, and slope | 0.278 (0.129, 0.387)<sup>e</sup> | 0.278 (0.164, 0.347)<sup>e</sup> | 0.257 (0.195, 0.326)<sup>e</sup> | 0.215 (0.119, 0.305)<sup>e</sup> |

Saturated model

| + CV          | −0.016 (−0.148, 0.170) | −0.029 (−0.081, 0.118) | −0.013 (−0.056, 0.088) | −0.009 (−0.062, 0.082) |
| + last_EGFR   | 0.196 (0.024, 0.359)<sup>e</sup> | 0.263 (0.140, 0.338)<sup>e</sup> | 0.233 (0.157, 0.308)<sup>e</sup> | 0.173 (0.090, 0.271)<sup>e</sup> |
| + slope_yr    | 0.057 (−0.040, 0.243) | 0.126 (0.016, 0.224)<sup>e</sup> | 0.144 (0.056, 0.225)<sup>e</sup> | 0.119 (0.005, 0.200)<sup>e</sup> |
| + CV, eGFR, and slope | 0.179 (0.058, 0.351)<sup>e</sup> | 0.280 (0.150, 0.359)<sup>e</sup> | 0.256 (0.161, 0.327)<sup>e</sup> | 0.186 (0.089, 0.258)<sup>e</sup> |

---

CV, coefficient of variation; eGFR, estimated glomerular filtration rate.

<sup>a</sup>Here follow-up time started after baseline period (i.e., 2 years posttransplantation).

<sup>b</sup>P < 0.001.

<sup>c</sup>P < 0.01.

<sup>d</sup>P < 0.05.
drafted the paper; BL, DAM, AD, and BCA participated in critical revision of the paper. All authors approved the final version of the manuscript.

**SUPPLEMENTARY MATERIAL**

Supplementary File (PDF)

**Supplementary Methods**

Table S1. Characteristics of excluded and enrolled patients

Table S2. Bivariable association between patient characteristic and risk of death within 10 years.

Table S3. Bivariable association between patient characteristic and risk of DCGF within 10 years.

Table S4. Continuous net reclassification index in risk of total graft loss risk prediction after including CV

Table S5. Variability of loglinear eGFR and the risk of outcomes

Table S6. Association between eGFR variability and competing risk analyses by patient characteristics

Table S7. Associations between eGFR variability and the risk of outcomes among KTRs not hospitalized between 1 and 2 years posttransplantation

Table S8. Associations between coefficient of variation of eGFR and outcomes of interest among transplantation between 2010 and 2014

Table S9. Association between variability of eGFR and outcomes of interest limiting events happened at least 2.5 years posttransplantation

Table S10. Association between mean absolute residuals of eGFR and outcomes of interest

Table S11. Associations between root mean square error (RMSE) of eGFR and outcomes of interest

Table S12. Association between coefficient of variation of creatinine and outcomes of interest

**Figure S1.** Flow chart of study population

**Figure S2.** Associations between patient characteristics and the risk of death.

**Figure S3.** Associations between standardized CV and the risk of death censored graft failure.

**Figure S4.** Calibration plots at 3 (A), 5 (B), and 10 (C) years of risk of mortality using model that included age, sex, race, cause of ESKD, live donor, eGFR, eGFR slope and eGFR CV.

**Figure S5.** Calibration plots at 3 (A), 5 (B), and 10 (C) years of risk of graft failure using model that included age, sex, race, cause of ESKD, live donor, eGFR, eGFR slope and eGFR CV.

**STROBE Statement (PDF)**

**REFERENCES**

1. Coemans M, Süsal C, Döhler B, et al. Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. *Kidney Int*. 2018;94:964–973.

2. Hart A, Smith J, Skeans M, et al. OPTN/SRTR 2018 annual data report: kidney. *Am J Transplant*. 2020;20:20–130.

3. Selvin E, Juraschek SP, Eckfeldt J, et al. Within-person variability in kidney measures. *Am J Kidney Dis*. 2013;61:716–722.

4. Al-Aly Z, Balasubramanian S, McDonald JR, et al. Greater variability in kidney function is associated with an increased risk of death. *Kidney Int*. 2012;82:1208–1214.

5. Choi HY, Huh KH, Lee JG, et al. Variability of the estimated glomerular filtration rate in the first year after kidney transplantation is an independent risk factor for poor renal allograft outcomes: a retrospective cohort study. *PLoS One*. 2016;11:12.

6. Perkins RM, Tang X, Bengier AC, et al. Variability in estimated glomerular filtration rate is an independent risk factor for death among patients with stage 3 chronic kidney disease. *Kidney Int*. 2012;82:1332–1338.

7. Xie Y, Bowe B, Xian H, et al. Rate of kidney function decline and risk of hospitalizations in stage 3A CKD. *Clin J Am Soc Nephrol*. 2015;10:1946–1955.

8. Pilch NA, Rohan V, Rao V, et al. Renal function variability: an independent risk factor for graft loss and death following kidney transplantation. *Am J Nephrol*. 2018;47:191–199.

9. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150:604–612.

10. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*. 1999;94:496–509.

11. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med*. 1996;15:361–387.

12. Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculation to measure usefulness of new biomarkers. *Stat Med*. 2011;30:11–21.

13. Uno H, Tian L, Cai T, et al. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. *Stat Med*. 2013;32:2430–2442.

14. R Core Team. *R: A language and environment for statistical computing*. Vienna, Austria: R Foundation for Statistical Computing; 2020.

15. Perkins RM, Kirchner HL, Hartle JE, Bucaloju I. Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with stage 3 chronic kidney disease. *Clin Nephrol*. 2013;80:256.

16. Kasiske BL, Israni AK, Snyder JJ, et al. The relationship between kidney function and long-term graft survival after kidney transplants. *Am J Transplant*. 2011;11:466–475.

17. Schnitzler MA, Johnston K, Axelrod D, et al. Associations of renal function at 1-year after kidney transplantation with subsequent return to dialysis, mortality, and healthcare costs. *Transplantation*. 2011;91:1347–1356.

18. Clayton PA, Lim WH, Wong G, Chadban SJ. Relationship between eGFR decline and hard outcomes after kidney transplants. *Am J Soc Nephrol*. 2016;27:3440–3446.

19. Moranne O, Maillard N, Fafin C, et al. Rate of renal graft function decline after one year is a strong predictor of all-cause mortality. *Am J Transplant*. 2013;13:695–706.

20. Gera M, Slezk J, Rule AD, et al. Assessment of changes in kidney allograft function using creatinine-based estimates of glomerular filtration rate. *Am J Transplant*. 2007;7:880–887.